TELYF (TelyRx Holdings) YoY EBITDA Growth: -307.89% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TELYF TelyRx Holdings Inc TELYF
12 GF Score
Price $1.88
! 2 Warning Signs
View Full Analysis

What is TelyRx Holdings YoY EBITDA Growth?

TelyRx Holdings TELYF +1.62% 12 YoY EBITDA Growth is -307.89% as of Jun. 2026. GuruFocus rates TELYF with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. TelyRx Holdings's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -307.89%.

TelyRx Holdings's EBITDA per Share for the three months ended in Jun. 2026 was $-0.16.

TelyRx Holdings YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for TelyRx Holdings's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TelyRx Holdings YoY EBITDA Growth Chart

TelyRx Holdings Annual Data
Trend Dec23 Dec24 Dec25
YoY EBITDA Growth
0.00 -406.90 -9.52

TelyRx Holdings Quarterly Data
Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only 0.00 -3,200.00 -288.00 -1,988.89 -307.89
TELYF
12GF Score
TelyRx Holdings Inc TELYF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TelyRx Holdings YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

TelyRx Holdings's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.161--0.147)/ | -0.147 |
=-9.52 %

TelyRx Holdings's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.155--0.038)/ | -0.038 |
=-307.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -307.89% mean?
TelyRx Holdings (TELYF) has a YoY EBITDA Growth of -307.89% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for TelyRx Holdings and its competitors.
Is TelyRx Holdings' YoY EBITDA Growth too high?
TelyRx Holdings' current YoY EBITDA Growth is -307.89%. Overall, TelyRx Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does TelyRx Holdings' YoY EBITDA Growth compare to ?
TelyRx Holdings' YoY EBITDA Growth of -307.89% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for TelyRx Holdings and its competitors. TelyRx Holdings's current YoY EBITDA Growth is -307.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TelyRx Holdings stock overvalued right now?
TelyRx Holdings (TELYF) has a current YoY EBITDA Growth of -307.89%. The current YoY EBITDA Growth is -307.89%. TelyRx Holdings' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For TelyRx Holdings (TELYF), the current YoY EBITDA Growth is -307.89% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TelyRx Holdings Business Description

Comparable Companies
Other Exchanges TELY:Canada
Address 24761 US Highway 19 North, Clearwater, FL, USA, 33763
TelyRx Holdings Inc is a vertically integrated technology enabled healthcare and pharmacy services provider, operating a digital pharmacy platform that connects patients with independent, state-licensed providers. The TelyRx platform provides the Providers with access to a clinically focused electronic medical records system and the ability for them to electronically prescribe. TelyRx enables patient access to a risk-curated formulary of over 450 noncontrolled, and non-compounded prescription medications selected by the Providers to address a broad cross-section of everyday chronic and acute ailments.
12GF Score

Get the complete analysis for TELYF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.88
Price